Company-reported prevalence
AXPAXLI
Overview
| Field | Value |
|---|---|
| Drug | AXPAXLI (axitinib intravitreal implant and OTX-TKI) |
| Indication | Neovascular age-related macular degeneration |
| Disease | Wet AMD (wet age-related macular degeneration); exudative retinal diseases for the addressable-population statements |
| Company | Ocular Therapeutix (developer; holds worldwide commercial rights to AXPAXLI; its AffaMed Therapeutics license covers DEXTENZA and OTX-TIC only) |
| Documents searched | Ocular Therapeutix website home, retinal disease, AXPAXLI pipeline, and clinical trials pages (accessed October 2026); Ocular Therapeutix press releases dated June 2023, January 2024, February 2024, August 2024, December 2024, January 2025, May 2025, November 2025, December 2025, February 2026, April 2026, June 2026, August 2026, and September 2026; Form 10-K for 2024 (March 2025); Form 10-K for 2025 (February 2026); Form 10-Q for the quarter ended June 30, 2026 (August 2026); Investor Day presentation (June 2026); treatment burden presentation (August 2026); scientific and medical congress presentations posted on the Ocular Therapeutix investor website (February 2022 to April 2026) |
| Data as of | October 14, 2026 |
| Prepared by | AI research agent (Claude); not yet reviewed by a person |
Company statements of prevalence
United States
Number affected: Ocular Therapeutix website, October 2026
“1.8M Americans” (opens the source at this quote in a new tab)
“Wet Age-Related Macular Degeneration (AMD)” (opens the source at this quote in a new tab)
Cited source: 2.4 Market Scope 2025
(opens the full-size image in a new tab)Number affected: Ocular Therapeutix press release, September 2026
Cited source: None stated in the document.
(opens the full-size image in a new tab)Number affected: Ocular Therapeutix Investor Day presentation, June 2026
Cited source: None stated in the document.
(opens the full-size image in a new tab)Number affected: Ocular Therapeutix press release, June 2026
Cited source: None stated in the document.
(opens the full-size image in a new tab)Number affected: Ocular Therapeutix Form 10-K for 2025, February 2026
Cited source: 2.4 Market Scope 2025
(opens the full-size image in a new tab)Eligible population (exudative retinal diseases): Ocular Therapeutix Form 10-K for 2025, February 2026
Cited source: 2.4 Market Scope 2025
(opens the full-size image in a new tab)Number affected: Ocular Therapeutix press release, December 2025
Cited source: None stated in the document.
(opens the full-size image in a new tab)Number affected: Ocular Therapeutix press release, May 2025
Cited source: 2.3 Market Scope 2024
(opens the full-size image in a new tab)Eligible population (exudative retinal diseases): Ocular Therapeutix Form 10-K for 2024, March 2025
Cited source: 2.3 Market Scope 2024
(opens the full-size image in a new tab)Number affected: Ocular Therapeutix press release, January 2025
Cited source: 2.2 Market Scope 2023
(opens the full-size image in a new tab)Number affected: Ocular Therapeutix press release, February 2024
Cited source: 2.1 Market Scope 2022
(opens the full-size image in a new tab)Europe
No evidence found.
Global
Number affected (worldwide): Ocular Therapeutix press release, September 2026
Cited source: None stated in the document.
(opens the full-size image in a new tab)Number affected (worldwide): Ocular Therapeutix Form 10-K for 2025, February 2026
Cited source: 2.4 Market Scope 2025
(opens the full-size image in a new tab)Number affected (worldwide): Ocular Therapeutix press release, December 2025
Cited source: None stated in the document.
(opens the full-size image in a new tab)Number affected (worldwide): Ocular Therapeutix press release, January 2025
Cited source: 2.2 Market Scope 2023
(opens the full-size image in a new tab)Other countries and regions
No evidence found.
Geography not stated
Prevalence (share of all AMD): Ocular Therapeutix website, October 2026
Cited source: 2.5 Gehrs 2006
(opens the full-size image in a new tab)Sources the company cites
Market scope 2022
Reference as the company lists it
Passage carrying the figure
Not quoted: Proprietary market research report sold by Market Scope, LLC; no public copy exists, and the press release gives no address for it.
Market scope 2023
Reference as the company lists it
Passage carrying the figure
Not quoted: Proprietary market research report sold by Market Scope, LLC; no public copy exists, and the press release gives no address for it.
Market scope 2024
Reference as the company lists it, press release, May 2025
Reference as the company lists it, Form 10-K for 2024
Passage carrying the figure
Not quoted: Proprietary market research report sold by Market Scope, LLC; no public copy exists, and neither company document gives an address for it.
Market scope 2025
Reference as the company lists it, Form 10-K for 2025
Reference as the company lists it, retinal disease web page
Passage carrying the figure
Not quoted: Proprietary market research report sold by Market Scope, LLC; no public copy exists, and neither company document gives an address for it.
Gehrs 2006
Reference as the company lists it
Passage carrying the figure
References
- Gehrs 2006 (opens in a new tab)
- Ocular Therapeutix (2024) press release, February 2024 (opens in a new tab)
- Ocular Therapeutix (2025) Form 10-K for 2024 (opens in a new tab)
- Ocular Therapeutix (2025) press release, December 2025 (opens in a new tab)
- Ocular Therapeutix (2025) press release, January 2025 (opens in a new tab)
- Ocular Therapeutix (2025) press release, May 2025 (opens in a new tab)
- Ocular Therapeutix (2026) Form 10-K for 2025 (opens in a new tab)
- Ocular Therapeutix (2026) Investor Day presentation, June 2026 (opens in a new tab)
- Ocular Therapeutix (2026) press release, June 2026 (opens in a new tab)
- Ocular Therapeutix (2026) press release, September 2026 (opens in a new tab)
- Ocular Therapeutix (2026) retinal disease web page (opens in a new tab)